Berna DİLBAZ, Serdar DİLBAZ, Yetkin KARASU, Berfu DEMİR

ANTI-MÜLLERYEN HORMON SEVİYESİ FARKLI RECOMBİNANT FSH DOZLARI İLE DEĞİŞİR Mİ?

Bu çalışmanın amacı polikistik over sendromlu (PCOS) ve normoresponder hastalarda follikül stimule edici hormone (FSH) tedavisinin anti-mülleryen hormone (AMH) seviyelerini etkileyip etkilemediğini araştırmaktır. Bu amaçla PCOS'li infertil hastalar (n=30) iki gruba ayrıldı. Birinci gruba long luteal gonodotropin releasing hormon (GnRH) ve invitrofertilizasyon (IVF) (n=15) diğer gruba ise kontrollü overyen hiperstimulasyon ve intrauterin inseminasyon (COH-IUI) tedavisi uygulandı. Normoresponder non-PCOS (n=30) hasta grubu da COH-IUI tedavisi aldı. Tüm gruplarda AMH düzeyleri siklus içinde 3 kez ölçüldü (bazal, midsiklus, luteal). PCOS'li ve non-PCOS'li hastalarda AMH seviyesinin farklı FSH dozlarından etkilenip etkilenmediği araştırıldı. Kullanılan total gonadotropin dozu PCOS'li hastalarda daha yüksekti (p

DOES ANTI-MULLERIAN HORMONE LEVEL VARY AT DIFFERENT RECOMBINANT FSH DOSES?

The aim of this study was to compare intracycle variability of Anti-Mullerian Hormone (AMH) throughout controlled ovarian hyper stimulation (COH) with follicle stimulating hormone (FSH) treatment in women with Polycystic Ovary Syndrome (PCOS) and normoresponder infertile patients. Infertile PCOS (n=30) patients were grouped into two. In the first group 15 patients were treated with long luteal gonadotropin releasing hormone analogue (GnRHa) and invitro fertilization (IVF) and 15 PCOS patients were treated with COH-intrauterine insemination (IUI). Non-PCOS (n=30) patients were treated with COH-IUI. AMH was measured three times in all groups (basal, mid-cycle, luteal). AMH levels in PCOS and non-PCOS patients underwent different amount of exogenous FSH treatment were compared. AMH levels in the PCOS patients were 2-2.5 times higher than non-PCOS patients. Total gonodotropin dose used was higher in the PCOS patients (p

PDF

___

1)Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83: 3078.
2)Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89: 2745.
3)Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997; 67: 962-5.
4)Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007; 134: 196-201.
5)Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008; 90: 395-400.
6)Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-7.
7)Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010; 16: 231-45.
8)Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002; 77: 141-6.
9)Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89: 318-23.
10)Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D.Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88: 5957-62.
11)La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006; 21: 3103-7.
12)Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhäuser MH. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril. 2008; 89: 927-33.
13)Hadlow N, Brown SJ, Habib A, Wardrop R, Joseph J, Gillett M, et al. Quantifying the intraindividual variation of antimullerian hormone in the ovarian cycle. Fertil Steril. 2016; 106: 1230-7.
14)Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, et al. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab. 2013; 98: 2106-15.
15)Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007; 134: 196-201.
16)Lie Fong S, Schipper I, de Jong FH, Themmen AP, Visser JA, Laven JS. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. 2011; 96: 459-63.
17)Li Y, Nie M, Liu Y, Zhang W, Yang X. The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome. Gynecol Endocrinol. 2015; 31: 450-3.
18)Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004; 82: 1323-9.
19)Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD. Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet. 2009; 26: 383-9.
20)Sahmay S, Demirayak G, Guralp O, Ocal P, Senturk LM, Oral E, Irez T. Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. J Assist Reprod Genet. 2012; 29: 589-95.
21)Tremellen K, Kolo M. Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol. 2010; 50: 568-72.
22)Sahmay S, Guralp O, Aydogan B, Cepni I, Oral E, Irez T. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients. Gynecol Endocrinol. 2013; 29: 440-3.